NCT00901576View on ClinicalTrials.gov

A Drug Interaction Study of SPD503 and Concerta Administered Alone and In Combination in Normal Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

May 18, 2009

Primary Completion Date

July 6, 2009

Study Completion Date

July 6, 2009

Conditions
Healthy
Interventions
DRUG

SPD503

SPD503 (guanfacine hydrochloride) extended-release 4 mg orally administered tablets

DRUG

Concerta

CONCERTA (methylphenidate HCl) extended-release 36 mg orally administered tablets.

DRUG

SPD503 + Concerta

SPD503 4 mg + CONCERTA 36 mg orally administered tablets (taken together).

Trial Locations (1)

07601

Advanced Biomedical Research, Inc., Hackensack

Sponsors

Lead Sponsor

Shire
All Listed Sponsors
lead

Shire

INDUSTRY

NCT00901576 - A Drug Interaction Study of SPD503 and Concerta Administered Alone and In Combination in Normal Healthy Volunteers | Biotech Hunter | Biotech Hunter